Carvana Option Alert: Sep 19 $280 Calls at the Bid: 383 vs 3904 OI; Earnings 4/30 After Close [est] 

Carvana Option Alert: Sep 19 $280 Calls at the Bid: 383 @ $21.8 vs 3904 OI; Earnings 4/30 After Close [est] Ref=$211.165

Carvana Option Alert: Aug 15 $220 Puts Sweep (5) near the Ask: 183 vs 376 OI; Earnings 4/30 After Close [est] 

Carvana Option Alert: Aug 15 $220 Puts Sweep (5) near the Ask: 183 @ $47.588 vs 376 OI; Earnings 4/30 After Close [est] Ref=$201.0

Carvana Option Alert: Aug 15 $210 Puts Sweep (8) near the Ask: 174 vs 135 OI; Earnings 4/30 After Close [est] 

Carvana Option Alert: Aug 15 $210 Puts Sweep (8) near the Ask: 174 @ $38.75 vs 135 OI; Earnings 4/30 After Close [est] Ref=$207.74

Carvana Option Alert: May 16 $210 Calls at the Ask: 500 vs 2600 OI; Earnings 4/30 After Close [est] 

Carvana Option Alert: May 16 $210 Calls at the Ask: 500 @ $24.5 vs 2600 OI; Earnings 4/30 After Close [est] Ref=$206.39

Carvana (NYSE:CVNA) Bolsa

CARVANA CO

Carvana

Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.

Stock,Market,Or,Forex,Trading,Graph,And,Candlestick,Chart,Suitable

Earnings

Equities

News

Markets

Movers

$BTC

ASST

CVNA

GOOG

GOOGL

NVAX

QBTS

D-Wave Quantum Inc. (NYSE:QBTS), Asset Entities, Inc. (NASDAQ:ASST), Alphabet, Inc.

Las 5 acciones más populares del jueves: ¿Qué está pasando con D-Wave, Novavax, Carvana?

Movers_Stocks

AAOI

AFYA

AKBA

BTBT

DOCU

FUTU

GDOT

RBRK

RDUS

RGNX

RGTI

SMTC

SOUN

ULTA

Semtech sorprendió al mercado con ingresos y ganancias superiores a lo esperado. Inversores reaccionan ante este sólido desempeño trimestral.

Semtech, Rubrik, DocuSign, PagerDuty y otras acciones estadounidenses que suben el viernes

ENVX

GRAB

PLTR

TSLA

Tesla, Palantir, Carvana, Enovix, Grab Holdings: descubre qué movió el mercado y qué esperar de estas acciones clave.

Palantir, Carvana, Enovix, Grab, Tesla: 5 acciones que están en el radar de los inversores

Carvana Co

WIIM

Xilio Therapeutics shares are trading lower after the company announced it commenced a public offering of pre-funded warrants.

SABR

Sabre Agrees With Salamair, Utilizing Sabre's Marketplace To Enhance Salamair's Global Visibility, Expand Market Reach, And Drive Revenue Growth

CLEU

China Liberal Education shares are trading lower after the company announced it will be suspended from Nasdaq for failing to address a 20-F delinquency filing.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

NIVF

NewGen To Invest  $30M In Solana Digital Asset Staking

Safe &amp; Green Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) ("Safe &amp; Green Holdings" or the "Company"), a leading designer and fabricator of modular structures, and a developer of diversified platforms that advance critical infrastructure through sustainable innovation, announces the signing of a non-binding Letter of Intent ("LOI") to acquire Giant Containers Inc., a recognized leader in modular, container-based infrastructure solutions.
Under the terms of the LOI, Safe &amp; Green will acquire 100% of the issued and outstanding shares of Giant Containers. The transaction also includes the appointment of Giant's CEO, Daniel Kroft, as Vice President of Business Development at Safe &amp; Green.
The proposed acquisition remains subject to customary conditions, including satisfactory due diligence, final negotiation and execution of definitive agreements, board approvals, and any necessary regulatory approvals. Final terms in the definitive agreements are subject to change from the LOI, closing is anticipated on or before June 15, 2025.

SGBX

Safe & Green To Acquire 100% Of Issued And Outstanding Shares Of Giant Containers; Terms Not Disclosed

PSTV

PLUS Therapeutics shares are trading higher. The company reported Q1 financial results.

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains Seacoast Banking (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBCF#NASDAQ">SBCF</a>) with a Outperform and raises the price target from $31 to $32.

Price Target

Analyst Ratings

SBCF

Keefe, Bruyette & Woods Maintains Outperform on Seacoast Banking, Raises Price Target to $32

Guidance

The Campbell's Sees FY25 Adjusted EPS To Be At The Low End Of The Guidance Range Due To The Slower Than Anticipated Recovery In The Snacks Business, Excluding The Impact Of Tariffs

The U.S. Food and Drug Administration (FDA) on Saturday approved Moderna, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) mNexspike&nbsp;(mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Control and Prevention (CDC)</a>.
&#8220;The FDA approval of our third product, mNEXSPIKE&#8230;,&#8221; said Stéphane Bancel, Chief <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/ac45708511/moderna-receives-u-s-fda-approval-for-covid-19-vaccine-mnexspike" rel="noreferrer noopener">Executive Officer of Moderna</a>.
The FDA&#8217;s approval of mNEXSPIKE is based on results from a randomized, observer-blind, active-controlled Phase 3 trial, which enrolled approximately 11,400 participants aged 12 years and older.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids" rel="noreferrer noopener">Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For &#8216;Healthy&#8217; Pregnant Women, Children</a>
The primary efficacy objective was to demonstrate the non-inferior vaccine efficacy against COVID-19 starting 14 days after mNexspike compared to that after the comparator vaccine, mRNA-1273 (Spikevax), Moderna&#8217;s original COVID-19 vaccine.
Participants received either a 10 μg dose of mRNA-1283 or a 50 μg dose of mRNA-1273.
mRNA-1283 showed a 9.3% higher relative vaccine efficacy (rVE) compared to mRNA-1273 in individuals aged 12 years and older, and in a descriptive sub-group analysis, a 13.5% higher rVE in adults aged 65 and older.
In the Phase 3 trial, mRNA-1283 was found to have a similar safety profile to mRNA-1273, with fewer local reactions and comparable systemic reactions.
The most commonly solicited side effects were injection site pain, fatigue, headache and myalgia.
Moderna expects to have mNexspike available for eligible populations in the U.S. for the 2025-2026 respiratory virus season, alongside Spikevax and mRESVIA, the company&#8217;s approved respiratory syncytial virus (RSV) vaccine.
William Blair writes, &#8220;Approval of mRNA-1283 is an incremental win for Moderna, especially considering HHS Secretary Robert F. Kennedy Jr.&#8217;s negative public opinion on mRNA COVID-19 vaccines, and we continue to see autonomy and data-driven decisions at the FDA.&#8221;
&#8220;We do not see approval of mRNA-1283 as a massive boost to Moderna&#8217;s COVID-19 vaccine sales, which we believe are primarily driven by sentiment surrounding the vaccination market in general, but this is a critical step in the regulatory path for the combo flu/COVID vaccine product, mRNA-1083, which uses mRNA-1283 as the COVID-19 component of its formulation,&#8221; analyst Myles Minter writes.
Analyst Minter says Moderna is still facing challenges from new government policies, including <a target="_blank" href="https://www.benzinga.com/government/regulations/25/05/45663794/hhs-cancels-590m-moderna-bird-flu-vaccine-deal-casting-uncertainty-over-pandemic-preparedness-effort" rel="noreferrer noopener">losing about $700 million</a> in funding from the Department of Health and Human Services for its bird flu vaccine project.
In addition, William Blair writes that the company&#8217;s goal to break even by 2028 is overly optimistic since it would need to more than double its revenue—based on cash costs—to reach that target.
In May, the FDA approved Novavax, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) Nuvaxovid for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults 65 years and older and individuals 12 through 64 years who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19 (e.g. asthma, cancer, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45489838/u-s-fda-approves-bla-for-novavaxs-covid-19-vaccine" rel="noreferrer noopener">diabetes, obesity, smoking)</a>.
Achievement of the U.S. license approval has triggered a&nbsp;$175 million&nbsp;milestone payment from Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>).
Price Action: MRNA stock is up 4.82% at $27.84 during the premarket session at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/05/45703385/dell-wins-wall-street-praise-after-12-billion-ai-server-orders-solid-commercial-pc-demand" target="_blank" rel="noreferrer noopener">Dell Wins Wall Street Praise After $12 Billion AI Server Orders, Solid Commercial PC Demand</a></li>
</ul>
Photo by Wolfilser via Shutterstock

Biotech

Large Cap

Health Care

Trading Ideas

General

MRNA

Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals

Contracts

TAOP

Taoping Wins $2.8M Contract To Supply Hunan Xiuxiang Agricultural Technology With Designated Agricultural Products

Citigroup analyst Patrick Cunningham initiates coverage on RPM Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) with a Buy rating and announces Price Target of $135.

Initiation

Citigroup Initiates Coverage On RPM Intl with Buy Rating, Announces Price Target of $135

<ul>
<li>KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment on tardive dyskinesia using multiple clinically validated scales</li>
<li>Patients taking INGREZZA reported robust and clinically meaningful improvements in physical, social and emotional functioning</li>
<li>Improvements were seen as early as Week 4 after initial treatment with the lowest INGREZZA dose and sustained through Week 24</li>
<li>Even patients with milder uncontrolled movement severity were negatively impacted by their tardive dyskinesia at baseline and demonstrated meaningful improvements in tardive dyskinesia impact with INGREZZA treatment</li>
</ul>
SAN DIEGO, June 2, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439241-1&amp;h=2727807877&amp;u=https%3A%2F%2Fwww.neurocrine.com%2F&amp;a=Neurocrine+Biosciences%2C+Inc.">Neurocrine Biosciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) today announced new data from the Phase 4 KINECT-PROTM open-label study demonstrating robust and sustained improvements in physical, social and emotional functioning in patients with tardive dyskinesia taking once-daily INGREZZA&#xAE; (valbenazine) capsules. KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment, specifically INGREZZA, on tardive dyskinesia using multiple clinically validated scales, including the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439241-1&amp;h=1411550016&amp;u=https%3A%2F%2Fjpro.springeropen.com%2Farticles%2F10.1186%2Fs41687-023-00679-4&amp;a=Tardive+Dyskinesia+Impact+Scale">Tardive Dyskinesia Impact Scale</a>. The Tardive Dyskinesia Impact Scale is the only patient-reported outcome instrument designed for and validated in tardive dyskinesia patients that measures the physical, social and emotional impact of the involuntary movements of the condition. These results were presented at 2025 Psych Congress Elevate in Las Vegas.

NBIX

Neurocrine Biosciences Announces New Data From Phase 4 KINECT-PROTM Open-Label Study Showing Robust, Sustained Improvements In Physical, Social And Emotional Functioning In Patients With Tardive Dyskinesia Taking Once-Daily INGREZZA Capsules

Company's PALISADE-4 Phase 3 trial now expected to read out in the first half of 2026

VTGN

Vistagen Therapeutics Provides Update For U.S. Registration-Directed PALISADE-3 Phase 3 Trial Evaluating Fasedienol For Acute Treatment Of Social Anxiety Disorder

Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintains Hamilton Lane (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NASDAQ">HLNE</a>) with a Market Perform and lowers the price target from $162 to $155.

HLNE

Keefe, Bruyette & Woods Maintains Market Perform on Hamilton Lane, Lowers Price Target to $155

WETO

Webush International shares are trading higher after the company announced it signed a $300 million XRP treasury management agreement with Samara Alpha.

Ladenburg Thalmann analyst Paul Fremont downgrades NorthWestern Energy Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWE#NASDAQ">NWE</a>) from Buy to Neutral and lowers the price target from $57.5 to $56.

Downgrades

Ladenburg Thalmann Downgrades NorthWestern Energy Group to Neutral, Lowers Price Target to $56

Classover Holdings, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/KIDZ#NASDAQ">KIDZ</a>, KIDZW)) ("Classover" or the "Company"), a leading provider of live, interactive online learning, today announced it has entered into a securities purchase agreement with Solana Growth Ventures LLC for the issuance of up to $500 million in senior secured convertible notes, advancing its strategic initiative to build a Solana (SOL)-based treasury reserve
Key Highlights:
- The securities purchase agreement provides for the issuance of up to $500 million in senior secured convertible notes. An initial closing and funding of $11 million is expected to occur promptly after customary closing conditions have been satisfied.
- The notes may be converted by the holder into the Company's Class B common stock at an initial conversion price equal to 200% of the closing price of the Company's Class B common stock on the trading day immediately prior to the closing date, subject to adjustment as provided for in the notes.
- Under the agreement, Classover is required to allocate up to 80% of the net proceeds toward purchases of SOL (Solana), subject to certain terms and limitations.
- This new agreement complements Classover's previously announced $400 million equity purchase agreement, increasing the Company's total potential financing capacity to $900 million, dedicated to supporting its SOL acquisition strategy.
- Prior to this agreement, Classover had already initiated its SOL reserve strategy, having purchased 6,472 SOL for approximately $1.05 million - marking the first step in its long-term strategy to acquire, hold, and stake Solana ("SOL") tokens.
The Company is also exploring opportunities for acquiring discounted blocks of locked tokens, as part of its broader accumulation and treasury strategy.

KIDZ

KIDZW

Classover Holdings Enters Into Securities Purchase Agreement With Solana Growth Ventures For Issuance Of Up To $500M In Senior Secured Convertible Notes, Advancing Strategic Initiative To Build Solana-Based Treasury Reserve

Management

TELA

TELA Bio Appoints Jeffrey Blizard As President Effective Immediately

Dollar General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) will release its first-quarter financial results before the opening <a href="https://www.benzinga.com/quote/DG/earnings">bell on Tuesday, June 3.</a>
Analysts expect the company to report quarterly earnings at $1.49 per share, down from $1.65 per share in the year-ago period. Dollar General projects quarterly revenue of $10.29 billion, compared to $9.91 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On May 29, UBS analyst Michael Lasser maintained Dollar General with a Buy rating and raised the price target from $95 to $120.
With the recent buzz around Dollar General, some investors may be eyeing potential gains from the company's dividends too. As of now, Dollar General offers an annual dividend yield of 2.43%, which is a quarterly dividend amount of 59 cents per share ($2.36 a year).
To figure out how to earn $500 monthly from Dollar General, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Dollar General's $2.36 dividend: $6,000 / 2.36 = 2,542 shares.
So, an investor would need to own approximately $247,210 worth of Dollar General, or 2,542 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $1.158 = 508 shares, or $49,403 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
DG Price Action: Shares of Dollar General gained by 0.2% to close at $97.25 on Friday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38289870/top-5-tech-and-telecom-stocks-that-may-rocket-higher-this-month">Top 5 Tech And Telecom Stocks That May Rocket Higher This Month</a></li>
</ul>
Photo: Shutterstock

Long Ideas

How To Earn $500 A Month From Dollar General Stock Ahead Of Q1 Earnings

ARVN

Arvinas shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and cut its price target from $10 to $9.

Press Releases

Carvana Announces Auction-IRC 'Megasite' Integration in Colorado Springs

ADESA Clear Expansion Unlocks Seamless Digital Auction Offering for Wholesale Auto Buyers Across the Country

Carvana to Present at Upcoming J.P. Morgan Global Technology, Media and Communications Conference

Carvana Announces Record First Quarter 2025 Results

Carvana and PPA Tour Build on Successful Title Sponsorship with New Multi-Year Partnership

Carvana Unveils Jimmie Johnson's 700th Start Tribute Paint Scheme for Coca-Cola 600, Honoring NASCAR Legacy and Fallen Heroes

Carvana Brings Inspection and Reconditioning Center Capabilities to ADESA Nashville

Carvana to Present at Upcoming William Blair 45th Annual Growth Stock Conference

Carvana Expands Same-Day Delivery to Denver Area

Defiance Launches CVNX: The First 2X Long ETF for Carvana Co.

Advance Auto Parts

Asbury Automotive Group

AutoNation

ARKO

Autozi Internet Technology (Global) Ltd. - Class A Ordinary Shares

Autozi Internet Tech

AutoZone

Cango Inc. American Depositary Shares, each representing two (2) Class A Ordinary Shares

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
02:31 PMMar 31, 2025	CALL	$280.00	Sep 19, 2025	108	386	383	10	3904	TRADE	BEARISH
10:09 AMMar 28, 2025	PUT	$220.00	Aug 15, 2025	73	183	183	49	376	SWEEP	BEARISH
10:14 AMMar 27, 2025	PUT	$210.00	Aug 15, 2025	73	0	174	0	135	SWEEP	BEARISH
11:51 AMMar 26, 2025	CALL	$210.00	May 16, 2025	-18	532	500	20	2600	TRADE	BULLISH

Comments

Carvana

Unusual Options Activity for

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL